Genzyme Ireland's Waterford biologics plant cited for quality unit and data integrity failures across two licensed products.
What happened
FDA inspected the Genzyme Ireland facility in Waterford, Ireland from January 12 to January 20, 2026, and issued a Form FDA-483 listing inspectional observations at the close. Investigators found incomplete laboratory records, environmental monitoring records that could not be traced back to the instruments that generated them, testing repeated up to 11 times without documentation, and deviations cancelled without investigation. FDA reviewed the company's responses of February 10, February 26, and April 8, 2026 and found they did not address the underlying failure of the quality unit.
What FDA found
The quality unit did not make sure the products were made according to CGMP and met their specifications.
21 CFR 211.22Laboratory records were incomplete: repeated particulate excursions and test failures were left out of records, and one test was repeated up to 11 times without documentation.
21 CFR 211.194(a)Environmental monitoring records could not be traced to the specific air samplers, and logbooks did not match when staff actually entered and left the cleanrooms.
21 CFR 211.194(a)Staff used uncontrolled review checklists that were later thrown away, and changes to records could not always be traced to a person.
21 CFR 211.194(a)The firm cancelled many deviations without investigating the root cause or assessing the effect on the product.
21 CFR 211.192The investigation of Deviation QE-1679805 into orange material found in filling had inconsistencies, and its conclusion that there was no product impact was not adequately supported.
21 CFR 211.192
What FDA wants
FDA tells the company to explain how its quality unit failed to detect and prevent these violations and to describe systemic corrective actions, including a full assessment of the scope of data integrity problems, an expanded retrospective review of all cancelled deviations, and a revised investigation of Deviation QE-1679805. The written response is due within 15 working days of receiving the letter.
Who should pay attention
- hospitals and transplant centers that use Thymoglobulin
- clinicians and patients using Altuviiio for bleeding disorders
- quality units at sterile biologics manufacturers that rely on similar deviation and lab record practices
This is a summary. Read the original letter on fda.gov.